Novan’s Stock Surges As SB206 Can Potentially Shorten Duration Of Contagious Skin Disease
Novan Inc (NASDAQ:NOVN) has announced positive topline efficacy and safety results from the B-SIMPLE4 Phase 3 trial evaluating SB206, a topical…
Orthofix To Present At JMP Securities Life Sciences Conference Jun. 16
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will
Autolus Therapeutics Highlights Presentation Of AUTO1 Data At European Hematology Association Virtual Congress 2021
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a poster presentation related to AUTO1 (obecabtagene
Protagonist Therapeutics Highlights Presentation Of Phase 2 Rusfertide Data At European Hematology Association 2021 Virtual Congress.
Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced updated results from the ongoing Phase 2 study of rusfertide, an investigational new drug being evaluated
Curis Highlights Presentation Of Data From Ongoing Phase 1/2 Study Of CA-4948 At European Hematology Association 2021 Virtual Congress
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated data from its ongoing Phase 1/2 open-label, single arm, dose
Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes
Precigen Inc’s (NASDAQ:PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type…
Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease Candidate; Stock Tumbles
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the Phase 2 data evaluating VX-864 in alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype.
Why Did Orphazyme (ORPH) Shares Skyrocket As Much As 1387% Today?
Orphazyme A/S (NASDAQ: ORPH) shares skyrocketed over 300% in the regular session on Thursday.
What Happened: Shares of the Denmark-based biopharmaceutical firm touched an intraday high of $77.77, running up 1,387%.
aTyr Pharma Highlights Presentation Of Second Anti-NRP2 Antibody Of Antibody Engineering & Therapeutics Europe Virtual
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2.
aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm.